DiagnosTear Technologies Inc. News Releases

DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

Fri, 05 Jun 2026 08:30:00 -0400

Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx™ as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to therapy in Dry Eye Disease https://pubmed.ncbi.nlm.nih.gov/42206882/Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing innovative point-of-care diagnostic solutions for ocular diseases, is...

RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for needles and...

DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics

Tue, 12 May 2026 16:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for needles and...

DiagnosTear Technologies Inc. Announces Results of AGM

Thu, 07 May 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general meeting of shareholders (the "AGM") held today. Shareholders approved all matters recommended by management, including:Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn and John Sinclair as directors of the Company;The appointment...

DiagnosTear Technologies Inc. Announces Warrant Extension

Mon, 04 May 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") announces that it has extended the expiry date of 5,733,885 outstanding common share purchase warrants (the "November 2024 Warrants") and 133,333 outstanding common share purchase warrants (the "December 2024 Warrants"). The November 2024 Warrants were issued in connection with a non-brokered private placement of subscription receipts and in...

DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting

Tue, 21 Apr 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR") framework, effective immediately. This change is being made pursuant to British Columbia Securities Commission Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").CBO 51-933 allows eligible venture issuers to voluntarily move from a...

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Thu, 26 Feb 2026 17:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce that it has obtained all required regulatory and ethics approvals to proceed with the clinical study of TeaRx™ Red Eye previously announced in a press release dated December 2, 2025.As previously disclosed, the Company initiated a collaboration with AlyaTec, a...

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

Fri, 20 Feb 2026 17:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics for ophthalmic conditions, today announced that it has entered into a Letter of Intent ("LOI") with Hanson Instruments Ltd. (trading as Hanson Medical), a United Kingdom-based supplier of ophthalmic and optometric equipment, to exclusively explore a commercial partnership for the TeaRx™ dry-eye...

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

Thu, 22 Jan 2026 17:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™ in India.The LOI is part of DiagnosTear's...

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Fri, 16 Jan 2026 19:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRx™ Red Eye diagnostic platform.TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed...